Overview
ATHE market data
Price History
ATHE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$0.10 Diluted earnings per share over the trailing twelve months.
- Beta
- 1.12 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -1,172.2% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $0.01 – $0.79 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $122.1M · P/B 0.88 · P/S 98.07.
Company News
Alterity Therapeutics shares are trading higher after the company announced it was granted a new composition of mater patent for ATH434 by the U.S. Patent and Trademark Office.Benzinga · Aug 12, 2026, 12:57 PM
Alterity Therapeutics Secures Key US Patent for Lead AssetBenzinga · Aug 12, 2026, 11:06 AM
Alterity Therapeutics Secures New US Patent for ATH434 Extending Protection to At Least 2045, And Enhancing Its Commercial PotentialBenzinga · Aug 12, 2026, 11:06 AM
Craig-Hallum Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $12Benzinga · Aug 11, 2026, 5:02 PM
Alterity Therapeutics Receives Official Meeting Minutes From Fda End-of Phase-2 Meeting For ATH434 In Multiple System Atrophy; Pivotal Phase 3 Trial Activities On Track To Initiate By End Of 2026Benzinga · Jul 7, 2026, 11:20 AM
Jones Trading Initiates Coverage On Alterity Therapeutics with Buy Rating, Announces Price Target of $16Benzinga · Jun 30, 2026, 1:25 PM
Alterity Therapeutics Advances Lead Drug Towards Pivotal Study For Rare Neuromuscular DisorderBenzinga · Jun 9, 2026, 3:45 PM
Alterity Therapeutics Announced Alignment With FDA On Pivotal Phase 3 ATH434 Program In Multiple System Atrophy; FDA Agrees To Phase 3 Design Including UMSARS Part I As Primary EndpointBenzinga · Jun 9, 2026, 11:15 AM
Alterity Therapeutics Presents On Multiple System Atrophy Program Including Its Novel Imaging And Biomarker Approach, Phase 2 Data, And Current Plans To Advance ATH434 Into Phase 3 Clinical Development.Benzinga · May 19, 2026, 11:35 AM